deltatrials
Completed PHASE3 NCT00101712

Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Sponsor: Novartis Pharmaceuticals

Conditions Diabetes Mellitus, Type 2
Interventions Vildagliptin Placebo vildagliptin
Updated 6 times since 2017 Last updated: May 4, 2012 Started: Oct 31, 2004 Primary completion: May 31, 2006 Completion: May 31, 2006

This PHASE3 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Novartis Pharmaceuticals leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Basel, Switzerland
  • • Investigative Site, Germany